Showing articles with keyword: Purdue University | CLEAR
January 18, 2018
Indiana CTSI to Host Annual Purdue Retreat
The Indiana CTSI’s annual retreat at Purdue University will be held from 8:30 a.m. to 3 p.m. on Friday, February 16, at the Burton D. Morgan Center for Entrepreneurship, located at 1201 W. State St. in West Lafayette, Indiana. This year’s event will feature sessions focused on new guidelines for nutrition clinical trials, the Indiana CTSI Postdoc Challenge, and analytical sciences in Indiana, as well as valuable networking opportunities with fellow researchers from across the state.
Please register by February 9. We hope to see you there!
Download the full agenda.
Get directions to the venue.
Questions? Email Indiana CTSI Purdue Navigator Tommy...
April 12, 2017
Purdue Study Finds Chemical-Weapon Antidote Shows Early Promise As Spinal Cord Injury Treatment
Indiana CTSI-supported research by Purdue University investigators has found that a Word War II-era chemical-weapon antidote shows early promise as a new treatment for spinal cord injuries.
Riyi Shi, a professor of neuroscience and biomedical engineering at Purdue, and Ran Tian, a graduate student at Purdue’s Weldon School of Biomedical Engineering, discovered that the antidote, a drug called dimercaprol, is effective at suppressing a neurotoxin that worsens the pain and severity of spinal cord injuries.
Read more: http://bit.ly/2o6LwSi
February 23, 2017
Purdue, IU scientists design epigenetic ‘key’ to editing neural stem cells
Scientists at Purdue University and Indiana University School of Medicine have developed a novel way to turn a gene on and off in the brain—a finding that could lead to new therapies for cancers and other genetic diseases.
Feng C. Zhou, PhD
Supported in part by the Indiana CTSI, the interdisciplinary team of neurologists and biological engineers discovered they could use a toolbox of light-sensitive proteins and enzymes, combined with a blue light, to alter the epigenetic state of the gene Ascl1, which acts as a switchboard telling stem cells in the brain what to turn into.
Their findings, recently published in...
January 18, 2017
Applications Sought for Design and Biostatistics Program Pilot Grant
Design and Biostatistics Program (DBP) Pilot Grant – 2017.02
LETTER OF INTENT (LOI) DEADLINE – DECEMBER 16, 2016
FULL APPLICATION DEADLINE – FEBRUARY 6, 2017 (5:00 PM)
The Design and Biostatistics Program (DBP) of the Indiana Clinical and Translational Science Institute (CTSI) is comprised of 8 units with associated expertise: 1) Department of Biostatistics, IU School of Medicine and Fairbanks School of Public Health; 2) Division of Hereditary Genomics, Department of Medical & Molecular Genetics, IU School of Medicine; 3) Computational Biology, Center for Computational Biology & Bioinformatics, IU School of Medicine; 4) Department of Epidemiology, Fairbanks School of Public Health; 5)...
January 10, 2017
Applications Sought for IIMR VA Young Investigator Award
LETTER OF INTENT (LOI) DEADLINE- JANUARY 18, 2017
APPLICATION SUBMISSION DEADLINE – FEBRUARY 08, 2017
IIMR’s mission is to promote and enhance research efforts that will ultimately result in improved quality of life for veterans and for the greater population. In support of that mission, IIMR works to encourage investigators to develop their research careers by working with IIMR and the VA and veterans to answer important questions. One way IIMR encourages investigators is to sponsor the annual Young Investigator Award Program, which provides a competitive experience for investigators to explore the possibilities of VA-related research.
The IIMR is currently seeking submissions...
November 1, 2016
Carmel Egan Joins Indiana CTSI
Carmel Egan, PhD
Carmel Egan, PhD, a top project management and product development executive at Eli Lilly and Co., has joined the Indiana University School of Medicine as project leader of IU’s Precision Health Initiative.
Dr. Egan, vice president, Medicines Development Unit at Lilly, has held a series of leadership positions at Lilly. Prior to her most recent position at Lilly, she served as Vice President of special Alzheimer’s disease initiatives in Lilly’s Biomedicines Business Unit and previously as Vice President of LRL Portfolio and Project Management.
She will coordinate activities of the Precision Health Initiative as part of her role as...